Cargando…
Metformin and Type 2 Diabetes Prevention
IN BRIEF Metformin, an established therapy for the treatment of type 2 diabetes, has demonstrated safety and effectiveness in the prevention or delay of type 2 diabetes in people at high risk. The Diabetes Prevention Program randomized clinical trial demonstrated that intensive lifestyle interventio...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243218/ https://www.ncbi.nlm.nih.gov/pubmed/30510389 http://dx.doi.org/10.2337/ds18-0020 |
_version_ | 1783371940529963008 |
---|---|
author | Aroda, Vanita R. Ratner, Robert E. |
author_facet | Aroda, Vanita R. Ratner, Robert E. |
author_sort | Aroda, Vanita R. |
collection | PubMed |
description | IN BRIEF Metformin, an established therapy for the treatment of type 2 diabetes, has demonstrated safety and effectiveness in the prevention or delay of type 2 diabetes in people at high risk. The Diabetes Prevention Program randomized clinical trial demonstrated that intensive lifestyle intervention and metformin therapy reduced progression to diabetes by 58 and 31%, respectively, compared to placebo in people at risk of type 2 diabetes. Although lifestyle intervention was beneficial in all groups, metformin had a selectively greater effect in those who were more obese, had a higher fasting glucose, had a history of gestational diabetes, or were younger. Long-term effects included an 18% diabetes reduction with metformin compared to placebo over 15 years, a reduction in microvascular complications among those who did not progress to diabetes (without difference among treatment arms), and suggestion by coronary calcium assessment of a possible impact on atherosclerosis in men. Although long-term follow-up to assess later-stage outcomes is underway, current efforts to address gaps in evidence and translation remain of significant public health interest. |
format | Online Article Text |
id | pubmed-6243218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-62432182019-11-01 Metformin and Type 2 Diabetes Prevention Aroda, Vanita R. Ratner, Robert E. Diabetes Spectr From Research to Practice IN BRIEF Metformin, an established therapy for the treatment of type 2 diabetes, has demonstrated safety and effectiveness in the prevention or delay of type 2 diabetes in people at high risk. The Diabetes Prevention Program randomized clinical trial demonstrated that intensive lifestyle intervention and metformin therapy reduced progression to diabetes by 58 and 31%, respectively, compared to placebo in people at risk of type 2 diabetes. Although lifestyle intervention was beneficial in all groups, metformin had a selectively greater effect in those who were more obese, had a higher fasting glucose, had a history of gestational diabetes, or were younger. Long-term effects included an 18% diabetes reduction with metformin compared to placebo over 15 years, a reduction in microvascular complications among those who did not progress to diabetes (without difference among treatment arms), and suggestion by coronary calcium assessment of a possible impact on atherosclerosis in men. Although long-term follow-up to assess later-stage outcomes is underway, current efforts to address gaps in evidence and translation remain of significant public health interest. American Diabetes Association 2018-11 /pmc/articles/PMC6243218/ /pubmed/30510389 http://dx.doi.org/10.2337/ds18-0020 Text en © 2018 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0 for details. |
spellingShingle | From Research to Practice Aroda, Vanita R. Ratner, Robert E. Metformin and Type 2 Diabetes Prevention |
title | Metformin and Type 2 Diabetes Prevention |
title_full | Metformin and Type 2 Diabetes Prevention |
title_fullStr | Metformin and Type 2 Diabetes Prevention |
title_full_unstemmed | Metformin and Type 2 Diabetes Prevention |
title_short | Metformin and Type 2 Diabetes Prevention |
title_sort | metformin and type 2 diabetes prevention |
topic | From Research to Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243218/ https://www.ncbi.nlm.nih.gov/pubmed/30510389 http://dx.doi.org/10.2337/ds18-0020 |
work_keys_str_mv | AT arodavanitar metforminandtype2diabetesprevention AT ratnerroberte metforminandtype2diabetesprevention |